Particle.news
Download on the App Store
7 ARTICLES
·
2d ago

GLP-1 Drugs Linked to Lower Cancer Risk in JAMA Oncology Study With Kidney-Cancer Signal

Researchers report a modest association from a large electronic-health-record analysis, calling for longer follow-up as well as randomized trials to test causality.

Boxes of Ozempic and Mounjaro, semaglutide and tirzepatide injection drugs used for treating type 2 diabetes and made by Novo Nordisk and Lilly, is seen at a Rock Canyon Pharmacy in Provo, Utah, U.S. March 29, 2023. REUTERS/George Frey/File Photo
Image
Hands in blue surgical gloves holding Ozempic injection pen.
Image

Overview

  • The propensity-matched OneFlorida+ cohort included 86,632 adults with overweight or obesity, split between 43,317 GLP-1 users and 43,315 nonusers with no prior cancer.
  • Overall cancer risk was lower in users (hazard ratio 0.83), with incidence rates of 13.6 vs 16.4 cases per 1,000 person-years.
  • Statistically significant associations were seen for endometrial (HR 0.75), ovarian (HR 0.53) and meningioma (HR 0.69) cancers.
  • A borderline elevation in kidney cancer was observed (HR 1.38; 95% CI, 0.99–1.93), a pattern also noted in earlier research and more apparent under age 65 in this analysis.
  • Authors highlight observational limits, low event counts for some tumors and lack of longitudinal BMI data, and they plan longer follow-up plus analyses using Indiana’s statewide EHR to inform prospective trials.